

AMVUTTRA® (vutrisiran)
may help

BRING LIFE'S MOMENTS WITHIN REACH

AMVUTTRA is the first and only injection given 4 times a year to treat the polyneuropathy of hereditary ATTR (hATTR) amyloidosis in adults*

Patient portrayal.

Patients receiving AMVUTTRA had significantly improved nerve function and quality of life at 9 months and continued to improve throughout an 18-month study compared to patients receiving placebo in a similar study.

*Dosing once every 3 months by a healthcare professional.

Important Safety Information

What are the most important things I should know about AMVUTTRA?

AMVUTTRA can cause:

- **Low Vitamin A Levels**

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor. (Continued on page 2)

Please see additional [Important Safety Information](#) on page 6 and full [Prescribing Information](#).

amvuttra
(vutrisiran) injection
25 mg/0.5 mL



Offering support as a caregiver

When a family member receives a diagnosis of hATTR amyloidosis and is prescribed AMVUTTRA® for the polyneuropathy caused by the disease, navigating symptoms of the disease and multiple doctor appointments can mean that loved ones have to become caregivers.

The role of a caregiver is a significant responsibility and can present challenges that require lifestyle changes for you and your loved one.

We're here to help. This guide provides you with information, tips, and suggestions that can help you support your loved one.

Important Safety Information

What are the most important things I should know about AMVUTTRA?

AMVUTTRA can cause:

- **Low Vitamin A Levels (cont.)**


Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

Please see additional [Important Safety Information](#) on page 6 and full [Prescribing Information](#).

Understanding hATTR amyloidosis

hATTR amyloidosis is a rare, inherited condition that affects multiple parts of the body. As a caregiver, it's important for you to be aware of the symptoms of hATTR amyloidosis, so you can help keep track of your loved one's condition and communicate effectively with their doctor.

Many of the symptoms of hATTR amyloidosis can affect a loved one's daily life, including:




Carpal tunnel syndrome



**Altered sensation
or loss of sensitivity**



Severe stomach issues



Unintentional weight loss



Loss of mobility



Dizziness upon standing

This is not a complete list of symptoms that may be experienced with hATTR amyloidosis.

**AMVUTTRA[®] does not treat all of the
symptoms of hATTR amyloidosis.**

Please see [Important Safety Information](#) on page 6 and full [Prescribing Information](#).

Your guide to AMVUTTRA®

Important things to remember

BEFORE	DURING	AFTER
<p>Keep track of appointment details:</p> <ul style="list-style-type: none"> • Take note of topics you may want to discuss with your loved one’s doctor • Plan reliable transportation to and from the appointment 	<p>Become familiar with how AMVUTTRA is administered:</p> <ul style="list-style-type: none"> • AMVUTTRA is an injection given by a healthcare professional, such as a doctor or nurse • AMVUTTRA is administered under the skin, in the upper arms, thighs, or abdomen 	<p>Make the next appointment to stay on schedule:</p> <ul style="list-style-type: none"> • AMVUTTRA is administered once every 3 months • You can work with your loved one’s doctor to choose where they receive AMVUTTRA—their doctor’s office, a local clinic, or their own home (depending on insurance)
<p>With AMVUTTRA treatment, no premedications or laboratory monitoring are required.</p>		

To learn more about AMVUTTRA, visit www.amvuttra.com

Important Safety Information

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA are pain in the arms or legs, pain in the joints (arthralgia), shortness of breath (dyspnea), and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional **Important Safety Information** on page 6 and full **Prescribing Information**.

Helpful tips for you

Caring for someone with a rare condition may require lifestyle changes. The following tips may offer you some help as you care for a loved one with the disease.

Learn about your loved one's condition—Understanding the symptoms of the disease and what to expect from treatment with AMVUTTRA® may help you feel more prepared for conversations with your loved one and their doctors.

Make a plan—Creating a schedule, including setting treatment appointments once every 3 months, can help you establish a routine with your family member that ensures they receive their treatment as prescribed.

Have an open dialogue—Talking with your loved one may help you form a stronger bond and allow you to share insights with doctors about their health and emotional well-being.

Take notes—Taking notes may make it easier to remember important information when talking to their doctors.

Explain your circumstances to others—Acting as a caregiver may sometimes require adjustments to your schedule or routine. You may need to explain to your employer, for example, how the condition impacts your loved one and disclose that you may need to occasionally take extra time to help them get to their doctor appointments.

Take time to care for yourself. It's important to look out for your own well-being when taking care of others. Continue to focus on your health with exercise, sleep, and a balanced diet.

Please see [Important Safety Information](#) on page 6 and full [Prescribing Information](#).

Indication and Important Safety Information



Indication

What is AMVUTTRA® (vutrisiran)?

AMVUTTRA is a prescription medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). AMVUTTRA is used in adults only.

Important Safety Information

What are the most important things I should know about AMVUTTRA?

AMVUTTRA can cause:

- **Low Vitamin A Levels**

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA are pain in the arms or legs, pain in the joints (arthralgia), shortness of breath (dyspnea), and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For additional information about AMVUTTRA, please see the full [Prescribing Information](#).

Finding help and resources

Connect with an Alynlam Educator



An Alynlam Patient Education Liaison (PEL) can provide education to help you and your loved one better understand the disease and answer your questions about AMVUTTRA®.

Alynlam PELs do not offer medical advice. Please talk to your loved one's doctor for specific concerns.


Visit www.amvuttraPEL.com to connect with an Alynlam Educator

Get patient support services through Alynlam Assist®



Alynlam Assist is a patient support program designed to help your loved one get started on treatment, understand their insurance coverage, determine eligibility for financial assistance, and provide ongoing support in their treatment journey with AMVUTTRA.

An Alynlam Case Manager will work with your loved one to begin treatment with and maintain access to AMVUTTRA.

 **1-833-256-2748**
Monday–Friday, 8AM–6PM

Financial assistance programs^a may include:

Alynlam Assist Commercial Copay Program^b covers certain out-of-pocket costs for eligible patients with commercial insurance.

Alynlam Assist Patient Assistance Program (PAP) provides AMVUTTRA at no cost to eligible patients, primarily the uninsured, who meet specified financial criteria.



To learn more, visit www.AlynlamAssist.com.

^aPatients must meet specified eligibility criteria to qualify for assistance. Alynlam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.

^bPatients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for the Alynlam Assist Commercial Copay Program. Out-of-pocket costs for the administration of AMVUTTRA will not be covered for patients residing where it is prohibited by law or where otherwise restricted.

Connect with someone who understands

There are advocacy and support groups locally and nationally that can help you connect with people who share similar caretaking experiences, questions, and concerns.

Amyloidosis Foundation
www.amyloidosis.org

The Foundation for Peripheral Neuropathy
www.foundationforpn.org

Amyloidosis Research Consortium
www.arci.org

Global Genes
www.globalgenes.org


Amyloidosis Support Groups
www.amyloidosisupport.org

National Alliance for Caregiving (NAC)
www.caregiving.org

Caregiver Action Network (CAN)
www.caregiveraction.org

National Organization for Rare Disorders
www.rarediseases.org

To learn more about AMVUTTRA® (vutrisiran),
please scan the QR code or visit www.amvuttra.com



Please see [Important Safety Information](#) on page 6 and full [Prescribing Information](#).



AMVUTTRA, Anylam Assist, and their associated logos are trademarks of Anylam Pharmaceuticals, Inc.
© 2024 Anylam Pharmaceuticals, Inc. All rights reserved.
AMV-USA-00300-V2

